内容概要：我国高血压、心力衰竭、心律失常等心血管疾病的患病人群总量庞大，且随着人口老龄化加 剧、居民生活方式改变，这类慢性疾病的发病率仍在稳步上升，琥珀酸美托洛尔缓释片凭借长效平稳的 药效、优异的用药依从性，成为心血管疾病的一线与基础治疗药物，临床不可替代性突出，拥有天然的 刚性需求，据药通社数据显示，2022年我国琥珀酸美托洛尔缓释片销售额达32.3亿元，同比增长4.7%， 但近几年，受集采降价影响，我国琥珀酸美托洛尔缓释片销售额有所下滑，2024年我国琥珀酸美托洛尔 缓释片销售额降至23.9亿元，同比减少4.6%，2025年上半年我国琥珀酸美托洛尔缓释片销售额共计完成 13.7亿元。 上市企业：东阳光（600673）、华海药（600521） 相关企业：阿斯利康制药有限公司、合肥合源药业有限公司、南通联亚药业股份有限公司、华益泰康药 业股份有限公司、浙江普洛康裕制药有限公司、佛山德芮可制药有限公司、广西厚德药业有限公司、宜 昌人福药业有限责任公司、重庆药友制药有限责任公司 关键词：琥珀酸美托洛尔缓释片行业相关政策汇总、琥珀酸美托洛尔缓释片产业链图谱、琥珀酸美托洛 尔缓释片销售额、琥珀酸美托洛尔缓释片竞争格局 ...

Core Viewpoint - Nantong Lianya Pharmaceutical Co., Ltd. (Lianya Pharmaceutical) is facing significant challenges in its IPO journey, having previously attempted to list on the Sci-Tech Innovation Board and now shifting to the ChiNext Board, despite showing impressive revenue and net profit growth over the past three years. However, underlying issues such as product dependency, governance stability, and independence concerns are evident [1][10]. Financial Performance - Lianya Pharmaceutical reported revenues of 700 million yuan, 866 million yuan, and 441 million yuan for the years 2023, 2024, and the first half of 2025, respectively, with year-on-year growth rates of 27.33% and 23.67% for 2023 and 2024 [2][11]. - The net profit attributable to the parent company for the same periods was 116 million yuan, 260 million yuan, and 103 million yuan, with growth rates of 2.47% and 124.68% for 2023 and 2024 [2][11]. Product Dependency - Lianya Pharmaceutical's core business focuses on the research, production, and sales of complex drug formulations, with a significant reliance on its main product, Metoprolol Succinate Extended-Release Tablets, which accounted for approximately 54.69% of revenue in the first half of 2025, showing a trend of increasing dependency [2][11][12]. Market Dynamics - The company has faced a challenging pricing environment in the U.S. market, where its flagship product is caught in a cycle of price reductions, unstable market share, and negative revenue sharing, leading to losses of 11.03 million yuan in 2023 and 12.80 million yuan in 2024 [5][14]. - Despite a rapid increase in domestic revenue due to centralized procurement, foreign sales still represented a significant portion of total revenue, accounting for 58.41% in the first half of 2025 [4][13]. Governance and Control Issues - Recent changes in control structure, including the death of a key controlling shareholder and the cancellation of special voting rights, have raised concerns about governance stability and the potential for control disputes, especially as external shareholders now hold a significant influence over the company [7][9][16]. - The top ten external shareholders have complex relationships, with the second-largest shareholder holding 20.61% and combined holdings exceeding that of the controlling shareholder, indicating a potential alignment of interests that could impact governance [8][17].

Group 1: Company Insights - iFlytek has accumulated over 50TB of industry corpus and over 1 billion user interactions daily across various industries, enhancing its data quality and diversity [1] - The "Xunfei Spark Model" has been upgraded to version 4.0, which significantly improves its foundational capabilities, now comparable to GPT-4 Turbo, with enhanced multimodal and intelligent agent capabilities [1] - Proloong Pharmaceutical has established long-term partnerships with several leading global pet medicine companies [2] - Proloong's product offerings include medications for the aging population, such as sustained-release metoprolol and indapamide for hypertension [2] - Proloong's existing business in medical beauty raw materials exceeds 200 million yuan, focusing on cosmetics, beauty products, and collagen, with potential future expansion into botulinum toxin products [2] Group 2: Fund Management Insights - Zhonghang Fund, established in 2016, has an asset management scale of 40.632 billion yuan, ranking 91 out of 210 in total public funds [2] - The fund's non-monetary public fund management scale is 40.408 billion yuan, ranking 84 out of 210 [2] - The fund manages 58 public funds, ranking 97 out of 210, with 19 fund managers, ranking 73 out of 210 [2] - The best-performing public fund in the past year is Zhonghang Opportunity Leading Mixed Fund A, with a latest net value of 2.97 and a growth of 115.7% over the past year [2] - The latest public fund product launched is Zhonghang Monthly Xin 30-Day Holding Period Bond A, which is a long-term bond type, with a subscription period from October 13 to October 24, 2025 [2]

Group 1: Company Insights - Longsheng Fund recently conducted research on two listed companies: iFlytek and Prolo Pharmaceutical [1][2] - iFlytek has accumulated over 50TB of industry corpus and over 1 billion user interactions daily, enhancing its data quality and multi-modal capabilities with the upgrade of its "Xunfei Spark Model" to version 4.0, which benchmarks against GPT-4 Turbo [1] - Prolo Pharmaceutical has established long-term partnerships with leading global pet medicine companies and has products targeting aging populations, such as sustained-release metoprolol and indapamide for hypertension [2] Group 2: Financial Performance - Longsheng Fund, established in 1999, has an asset management scale of 96.309 billion yuan, ranking 64th out of 210 in total public funds [2] - The fund's non-monetary public fund management scale is 65.487 billion yuan, ranking 63rd out of 210 [2] - The best-performing public fund in the past year is the Longsheng Urbanization Theme Mixed C, with a latest net value of 2.67 and a growth of 84.29% over the past year [2]

Group 1: Company Insights - Keda Xunfei has accumulated over 50TB of industry corpus and over 1 billion daily user interactions, enhancing its data quality across multiple sectors [1] - The company has upgraded its "Xunfei Spark Model" to version 4.0, which significantly improves its multimodal and intelligent agent capabilities, comparable to GPT-4 Turbo [1] - Liyuanheng has delivered full solid-state battery production line equipment to a leading automotive company, currently in the debugging and process validation stages [2] - The company reported a revenue of 2.424 billion yuan for the first nine months of 2025, a year-on-year increase of 4.37%, with a net profit of 47.49 million yuan [2] - Prolo Pharmaceutical has established long-term partnerships with several leading global pet medicine companies and has products targeting aging populations [3] - The company has over 200 million yuan in business related to medical beauty raw materials, focusing on cosmetics and collagen products in the short term [3] Group 2: Fund Management Insights - Nanhua Fund, established in 2016, has an asset management scale of 21.526 billion yuan, ranking 121 out of 210 in total public funds [3] - The fund's best-performing public fund product in the past year is Nanhua Fenghui Mixed A, with a latest net value of 1.86 and a growth of 49.35% over the past year [3]

Core Viewpoint - Huayi Taikang Pharmaceutical Co., Ltd. is progressing with its IPO guidance, with the guidance period set from April 1, 2025, to June 30, 2025, after starting the IPO filing on January 26, 2024 [2] Company Overview - Huayi Taikang was established in June 2010, focusing on the research, development, production, and sales of complex formulations and innovative formulations, providing one-stop, international pharmaceutical R&D and customized production services [3] - The company has a registered capital of 60.048 million yuan and is legally represented by Zhu Honggang [3] Product Portfolio - The main products approved for sale include sustained-release metoprolol succinate tablets, enteric-coated paroxetine sustained-release tablets, tacrolimus capsules, enteric-coated esomeprazole magnesium capsules, and agomelatine tablets, primarily used in treating hypertension, depression, organ transplantation, digestive system, and neurological diseases [4] Financial Performance - Revenue for Huayi Taikang from 2022 to 2024 was 113 million yuan, 258 million yuan, and 308 million yuan respectively, with net profits of -40.59 million yuan, 65.64 million yuan, and 59.40 million yuan [5] - In Q1 2025, the company reported revenue of 85.24 million yuan, a year-on-year increase of 30.41%, and a net profit of 28.46 million yuan, a year-on-year increase of 175.71% [6][8] - The basic earnings per share for Q1 2025 was 0.47 yuan, compared to 0.18 yuan in the same period last year [8]

Group 1 - Huayi Taikang Pharmaceutical Co., Ltd. (Huayi Taikang) has initiated its IPO counseling process, with the counseling period set from April 1, 2025, to June 30, 2025 [3] - The counseling includes all directors, supervisors, senior management, and shareholders holding more than 5% of the shares [3] - The company has appointed Wang Jin as a new director during the counseling period [3] Group 2 - Established in June 2010, Huayi Taikang focuses on the research, production, and sales of complex and innovative formulations, providing one-stop international pharmaceutical R&D and customized production services [4] - The company has received approval for several key products, including Succinic Acid Metoprolol Sustained-Release Tablets and Tacrolimus Capsules, which are primarily used in treating hypertension, depression, organ transplants, and digestive and neurological diseases [4] - Revenue figures for Huayi Taikang from 2022 to 2024 are 113 million, 258 million, and 308 million yuan, respectively, with net profits of -40.59 million, 65.64 million, and 59.40 million yuan [4] Group 3 - In the first quarter of 2025, Huayi Taikang reported revenue of 85.24 million yuan, a year-on-year increase of 30.41%, and a net profit of 28.46 million yuan, up 175.71% [5] - The company’s basic earnings per share for the first quarter of 2025 is 0.47 yuan, compared to 0.18 yuan in the same period last year [6] - The weighted average return on equity based on net profit attributable to shareholders for the first quarter of 2025 is 7.31%, up from 4.69% in the previous year [6] Group 4 - Zhu Honggang is the controlling shareholder and actual controller of Huayi Taikang, holding a direct stake of 1.58% and controlling a total of 36.78% of the voting rights through various entities [6] - Zhu Honggang has a background in pharmaceutical sciences, holding a Ph.D. from the University of Utah, and has held various managerial positions in the pharmaceutical industry since 2003 [8]

Core Viewpoint - Nantong Lianya Pharmaceutical Co., Ltd. has received acceptance for its IPO on the ChiNext board, entering the inquiry stage, with CICC as the sponsor. The company focuses on the research, production, and sales of complex drug formulations, primarily targeting hypertension and coronary heart disease, with significant market share in the U.S. [1][5] Financial Performance - The company projects revenues of 866 million yuan and net profits of 260 million yuan for 2024, with historical revenues of 550 million yuan in 2022 and 700 million yuan in 2023 [3][4]. - Cumulative net profits for 2022, 2023, and 2024 are expected to be 113 million yuan, 116 million yuan, and 260 million yuan respectively [3][4]. IPO Financing and Project Allocation - The IPO aims to raise 950 million yuan, allocated as follows: 306 million yuan for production base construction, 266 million yuan for R&D center construction, 328 million yuan for drug research projects, and 50 million yuan for working capital [1][2]. R&D Investment - The company has invested a total of 293 million yuan in R&D over the past three years, with annual R&D expenditures of 103 million yuan in 2022, 88.73 million yuan in 2023, and 120 million yuan in 2024 [6]. - The R&D expense ratio for the same years was 18.70%, 12.67%, and 11.74%, compared to industry averages of 20.99%, 20.13%, and 18.64% [6]. Market Position and Product Portfolio - The company has a strong presence in the U.S. market, with several products ranked first in market share, including sustained-release formulations of Nifedipine and Diltiazem [5][6]. - The product pipeline includes 45 generic drug projects and 2 improved new drug projects, with 44 self-developed products approved by the FDA [6]. Shareholding Structure - Lianya Cayman directly holds 22.62% of the company's shares, making it the controlling shareholder. The actual controllers collectively hold 29.50% of the shares [7].

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the registration of two new drugs, which are expected to generate significant sales in the domestic market in 2024 [1] Group 1: Product Approvals - The company has obtained the drug registration certificate for Succinic Acid Metoprolol Sustained-Release Tablets, which are used for treating hypertension and angina, with an estimated domestic market sales amount of approximately 3.066 billion yuan in 2024 [1] - The company has also received approval for Nicardipine Hydrochloride Injection, intended for emergency treatment of abnormal hypertension during surgery, with an estimated domestic market sales amount of around 632 million yuan in 2024 [1] Group 2: R&D Investment - The company has invested approximately 17.04 million yuan in the research and development of Succinic Acid Metoprolol Sustained-Release Tablets [1] - The investment in the research and development of Nicardipine Hydrochloride Injection amounts to about 4.98 million yuan [1]

Core Viewpoint - Nantong Lianya Pharmaceutical Co., Ltd. has successfully submitted its IPO application for the ChiNext board, marking the return of pharmaceutical companies to this market after nearly two years [1][3] Company Overview - Lianya Pharmaceutical focuses on the research, production, and sales of complex drug formulations, primarily offering high-end generic drugs, including controlled-release formulations and low-dose drug formulations [3] - The company has previously attempted to list on the Sci-Tech Innovation Board but withdrew its application after three rounds of inquiries [3][4] IPO Details - The company aims to raise 950 million yuan (approximately 9.5 billion yuan) for its IPO, a decrease from the previously planned 1.05 billion yuan (approximately 10.5 billion yuan) during its Sci-Tech Innovation Board application [1][5] - The funds will be allocated to industrialization base projects, drug research and development, and working capital [6] Fund Allocation - The industrialization base project will receive 306 million yuan for production base construction and 266 million yuan for R&D center construction, expected to add 1 billion tablets and 100 million capsules in production capacity [6] - The drug R&D project will receive 328 million yuan, focusing on 28 product pipelines across various therapeutic areas, including gynecology, hypertension, central nervous system disorders, and diabetes [6] Financial Performance - Lianya Pharmaceutical has shown increasing net profits, with projected revenues of approximately 550 million yuan, 700 million yuan, and 866 million yuan for the years 2022 to 2024, respectively [8] - Corresponding net profits are expected to be around 113 million yuan, 116 million yuan, and 260 million yuan for the same period [8] Customer Dependency - The company has a significant reliance on its largest customer, Ingenus, which accounted for over 50% of its revenue during the reporting period [9] - Revenue from Ingenus was approximately 398 million yuan, 397 million yuan, and 449 million yuan for the years 2022 to 2024, representing 72.36%, 56.63%, and 51.87% of total revenue, respectively [9][10] - Ingenus is a comprehensive pharmaceutical company based in the U.S., focusing on the development and commercialization of generic drugs [10]